Supernus Pharmaceuticals
SUPN
$29.31
Share price
-3.14%
Change (1 day)
-22.28%
Change (1 year)
Categories
P/S ratio for Supernus Pharmaceuticals (SUPN)
P/S ratio as of April 2024 (TTM): 2.73
According to Supernus Pharmaceuticals 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 2.72629. At the end of 2023 the company had a P/S ratio of 2.60.
P/S ratio history for Supernus Pharmaceuticals from 2012 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 2.60 | -9.95% |
| 2022 | 2.89 | 8.04% |
| 2021 | 2.67 | 4.64% |
| 2020 | 2.56 | -19.44% |
| 2019 | 3.17 | -25.35% |
| 2018 | 4.25 | -37.11% |
| 2017 | 6.76 | 16.17% |
| 2016 | 5.82 | 29.35% |
| 2015 | 4.50 | 16.32% |
| 2014 | 3.87 | -84.58% |
| 2013 | 25.1 | -83.1% |
| 2012 | 148 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 3.85 | 41.13% | 🇺🇸 USA |
 Abbott Laboratories ABT | 4.62 | 69.62% | 🇺🇸 USA |
 Eli Lilly LLY | 20.4 | 648.29% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 2.20 | -19.29% | 🇺🇸 USA |
 Zogenix ZGNX | N/A | N/A | 🇺🇸 USA |
 United Therapeutics UTHR | 4.79 | 75.76% | 🇺🇸 USA |